Background
==========

There has recently been substantial progress in the development of new therapeutic strategies for the management of patients with pulmonary hypertension (PHT) \[[@B1]-[@B5]\]. The improvements are based on a better understanding of the mechanisms involved in the development of PHT. These treatment strategies are based on the recognition that a key role is played in the modulation of the tone of the smooth muscle cells in the pulmonary vasculature by an imbalance between the vasoactive constrictor and proliferative mediators (endothelin-1 (ET-1), substance P and angiotensin II) and the vasorelaxing and antiproliferative mediators (adrenomedullin, vasoactive intestinal peptide (VIP), prostacyclins (PCs) and nitric oxide (NO)) \[[@B6]\]. The bronchoactive potential of these peptides has been recognized as the major cause of the lung function deterioration \[[@B1],[@B2],[@B7]-[@B10]\].

We earlier reported a lung function impairment in a reproducible model of precapillary PHT following the creation of a shunt between the abdominal aorta and the vena cava in rats \[[@B11]\]. We also demonstrated that precapillary PHT leads to the development of bronchial hyperresponsiveness (BHR) to methacholine subsequent to the altered mechanical interdependence between the pulmonary vasculature and the respiratory tract. Although novel strategies are available for the treatment of pulmonary vascular diseases, no studies have yet characterized how the adverse pulmonary consequences of these clinically important pulmonary vascular abnormalities can be prevented. Accordingly, in the present study we set out to explore the efficiency of treatment strategies designed to prevent the adverse changes in the lung function and bronchial responsiveness by acting on the imbalance between the vasoactive constrictor-proliferative and vasorelaxing-antiproliferative mediators.

Methods
=======

Animal preparations
-------------------

The experimental protocol was approved by the Experimental Ethics Committee of the University of Geneva and the Animal Welfare Committee of the Canton of Geneva. Fifty-six adult male Sprague-Dawley rats (weighing 312-382 g) were anaesthetized by an intraperitoneal injection of pentobarbital (70-90 mg/kg of a 50 mg/ml solution). Tracheal intubation was achieved with a polyethylene cannula (16-gauge, Braun, Melsungen, Germany) and the rats were mechanically ventilated with a tidal volume of 7 ml/kg body weight, a positive end-expiratory pressure of 2.5 cm H~2~O, and a respiratory rate of 70-80/min (model 683, Harvard Apparatus Co Inc., South Natick, MA, USA). Anesthesia was maintained with pentobarbital administered intravenously every 40 min (5 mg/kg). The femoral vein was cannulated for drug delivery. The airway pressure, ECG and rectal temperature were monitored continuously by a data collection and acquisition system (Biopac, Santa Barbara, CA, USA). Fentanyl was administered intravenously (15 μg/kg) to ensure adequate analgesia before the administration of pancuronium intravenously (0.4 mg/kg) to facilitate forced oscillatory measurements. To ensure adequate postoperative analgesia, buprenorphine (0.5 mg/kg) was injected subcutaneously before emergence from anesthesia and again 18 h after surgery.

Induction of precapillary pulmonary hypertension
------------------------------------------------

The surgical induction of precapillary PHT was performed as described in detail previously \[[@B11]-[@B13]\]. Briefly, a midline abdominal incision was made in a sterile manner and the infra-renal portions of the abdominal aorta and inferior vena cava were exposed at the site where the two vessels share a common fascia. An aorto-caval shunt (ACS) was then prepared by introducing a needle between the two vessels, followed by application of an aortic adventitial suture. In the rats that received various treatments (see below), an osmotic intraperitoneal pump (Alzet model 2ML4, Alza corporation, Palo Alto, USA) was implanted intraperitoneally into the lower abdomen in order to allow continuous delivery of the different drug medications during 4 weeks. The abdomen was closed in a sterile manner and a long-acting local anesthetic (bupivacaïne 0.25%, 0.8-1.2 ml) was infiltrated around the surgical wounds.

Treatments, protocol groups
---------------------------

After creation of the ACS, the animals were randomized to be included in one or other of the groups detailed below (Figure [1](#F1){ref-type="fig"}). The route of administration of the treatment agents and the doses were chosen on the basis of their pharmacokinetic properties and the manufacturers\' recommendations.

![**Experimental protocol**. Zrs: forced oscillatory recordings of the respiratory input impedance. MCh: methacholine.](1465-9921-12-58-1){#F1}

### Group CC (n = 13)

These control rats underwent the surgical procedure as detailed above, but without preparation of the ACS. A subgroup (n = 7) of these animals underwent sham surgery and implementation of an intraperitoneal pump for the continuous delivery of normal saline in the 4-week period, while the remaining rats were not implanted with the pump (n = 6). Since there was no difference between these sham subgroups in the data relating to any of the parameters measuring hemodynamics or respiratory mechanics, their data were pooled for further analyses.

### Group CS (n = 10)

An ACS was prepared in these animals, but no subsequent drug treatment was applied.

### Group VIP (n = 8)

To test the VIP pathway in affecting PHT and the subsequent BHR, rats with an ACS received VIP 150 μg/kg/day, administered via the intraperitoneal pump (2.5 μl/h) for 4 weeks.

### Group ILO (n = 10)

To study the PC pathway in influencing PHT and the subsequent BHR, rats with ACS received iloprost 80 μg/kg for 4 weeks via the intraperitoneal pump (5 μl/h).

### Group SIL (n = 7)

To investigate the role of NO in the precapillary PHT and the subsequent BHR, ACS preparation was followed by a 4-week treatment with sildenafil administered orally (25 mg/day dissolved in 1.5 ml saline).

### Group TEZ (n = 8)

To explore how the ET-1-related mechanisms affect the precapillary PHT and the subsequent BHR, rats with an ACS were treated for 4 weeks with the combined ET~A~-ET~B~receptor blocker tezosentan (10 mg/kg/day) administered via an intraperitoneal pump (2.5 μl/h).

Measurements of end-expiratory lung volume (EELV)
-------------------------------------------------

EELV measurements were accomplished in all groups with a body plethysmograph, as detailed previously \[[@B14]\]. Briefly, the trachea was occluded at end expiration until 3 or 4 spontaneous inspiratory efforts had been generated by the animal in the closed box. The changes in tracheal pressure and plethysmograph box pressure during these manoeuvres were recorded, and EELV was calculated by applying Boyle\'s law to the relationship between the tracheal pressure and the box pressure after correcting for the box impedance \[[@B15]\].

Forced oscillatory measurements
-------------------------------

The contributions of the airway and tissue mechanical properties to the total respiratory resistance were estimated by the forced oscillation technique by measuring the mechanical impedance of the respiratory system (Zrs), as described in detail previously \[[@B16],[@B17]\]. Briefly, the tracheal cannula was connected from the respirator to a loudspeaker-in-box system at end-expiration. Zrs was measured with the wave-tube technique by introducing pseudorandom forced oscillations at frequencies between 0.5 and 21 Hz at end-expiration. Two identical pressure transducers (Model 33NA002D, ICSensors, Malpitas, CA, USA) were used to measure the lateral pressures at the loudspeaker and at the tracheal end of the wave-tube, and Zrs was calculated as the load impedance of the wave-tube by using fast Fourier transformation \[[@B16]\].

To separate the airway and tissue mechanics, a model containing a frequency-independent resistance (Raw) and inertance (Iaw) in series with a constant-phase tissue model \[[@B18]\] including tissue damping (G) and elastance (H) was fitted to the Zrs spectra by minimizing the differences between the measured and modelled impedance values:

where j is the imaginary unit, is the angular frequency (2f) and = 2/arctan(H/G). When this model is fitted to Zrs spectra, the parameter Raw is primarily related to the overall airway geometry, as the contribution of the chest wall to the frequency-independent Newtonian resistance is minor \[[@B19]\]. Similarly, the inertia of the gas in the airways predominates in the parameter Iaw \[[@B19]\].

Measurement of pulmonary haemodynamics
--------------------------------------

The pulmonary arterial pressure (Ppa) was measured by introducing a small catheter (polyethylene tubing, ID 0.88 mm, Portex, Hythe, GB) into the pulmonary artery via the jugular vein beforethe animals were sacrificed. This measurement was technically acceptable only in subgroups of the main study groups, involving 7, 10, 4, 5, 2 and 6 rats in Groups CC, CS, VIP, ILO, SIL and TEZ, respectively.

Measurement protocol and bronchoprovocation challenges
------------------------------------------------------

Four weeks following the surgical preparation of ACS, the rats were again anaesthetized and intubated, and the experimental protocol was performed. EELV was first measured while the rats were breathing spontaneously. A femoral vein was then cannulated for drug delivery. When stable hemodynamic and respiratory mechanical conditions had been reached, a set of Zrs data including 4-6 6-s long recordings was recorded under the baseline conditions. Increasing doses of iv methacholine (MCh) were then administered at doses of 2, 4, 8, 12 and 24 μg/kg/min, and at each infusion rate 3-5 Zrs recordings were made during the development of steady-state bronchoconstriction (usually 3-5 min after the onset of MCh). The equivalent dose causing a 50% increase in Raw (ED~50~) was calculated in each rat by linear interpolation. Following these measurements, Ppa was measured as described above.

Statistical analyses
--------------------

The scatters in the parameters were expressed by the SE values. The Kolmogorov-Smirnov test was used to test data for normality. One-way analysis of variances (ANOVA) was performed to test significant differences in the parameters among the groups. Two-way repeated measures ANOVA, with variables of treatment (i.e. the protocol groups) and MCh dose, was used to evaluate the effects of the various types of medication on the precapillary PHT and subsequent lung responsiveness to the constrictor challenge. Pairwise comparisons were performed by means of Student-Newman-Keuls multiple comparison procedures. Pearson correlation test was used to assess the strength of associations between variables. Statistical tests were carried out with the significance level set at p \< 0.05.

Results
=======

There was no significant difference in body weight among the protocol groups either at the beginning of the study (ranging from 340 ± 9 g to 360 ± 4 g, p = 0.11) or at the time of the experiments 4 weeks later (ranging from 413 ± 14 g to 454 ± 12 g, p = 0.1).

Figure [2](#F2){ref-type="fig"} demonstrates the systolic and diastolic values of Ppa for the various groups. Preparation of the ACS led to a significant increase in systolic Ppa (p = 0.036). This PHT was significantly inhibited only by iloprost (p = 0.035); none of the other treatments affected the alteration in Ppa. No change in the diastolic Ppa was detected (p = 0.15).

![**Systolic (top of the bars) and diastolic (bottom of the bars) pulmonary arterial pressures in the rats involved in the different groups**. CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan. \*: p \< 0.05 vs the data obtained in the rats with precapillary pulmonary hypertension with no drug treatment (Group CS).](1465-9921-12-58-2){#F2}

The baseline in the EELV and the forced oscillatory parameters in the different groups are displayed in Figure [3](#F3){ref-type="fig"}. ACS preparation and subsequent treatments did not affect the basal lung volume (p = 0.22), the basal Raw (p = 0.28) or the respiratory tissue parameters (p = 0.45).

![**The baseline end-expiratory lung volume (EELV), airway resistance (Raw), respiratory tissue damping (G) and elastance (H) data obtained in the different groups**. CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan.](1465-9921-12-58-3){#F3}

Figure [4](#F4){ref-type="fig"} depicts the airway responses to MCh challenges in the groups. MCh induced a dose-dependent bronchoconstriction of various magnitude in all groups. ACS preparation led to the development of BHR, as illustrated by the significant upward shift in the dose response-curve. Each of the drug treatments exerted a protective effect against this hyperresponsiveness to MCh. The MCh-induced changes in G and H were far more moderate and did not exhibit a statistically significant difference among the groups (p = 0.45, and p = 0.26 for G and H, respectively; Table [1](#T1){ref-type="table"}).

![**Methacholine-induced changes in airway resistance (Raw) in the different groups**. CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan. \*: p \< 0.05 vs the value obtained under baseline conditions (BL) within a group; \#: p \< 0.05 vs. the data obtained in the rats with precapillary pulmonary hypertension without drug treatment (Group CS).](1465-9921-12-58-4){#F4}

###### 

Respiratory tissue parameters under baseline conditions, during MCh infusion at a dose of 24 μg/kg/min, and their percentage changes in the different groups

        **G (cmH**~**2**~**O/l)**   Change in G   **H (cmH**~**2**~**O/l)**   Change in H                  
  ----- --------------------------- ------------- --------------------------- ------------- -------------- ---------
  CC    866 ± 49                    1150 ± 76\*   33 ± 5                      2927 ± 299    3767 ± 334\*   31 ± 4
  CS    736 ± 42                    968 ± 78\*    31 ± 5                      2936 ± 167    3329 ± 195\*   15 ± 6
  VIP   735 ± 33                    991 ± 49\*    37 ± 10                     2589 ± 258    3139 ± 231\*   24 ± 5
  ILO   802 ± 84                    930 ± 65\*    21 ± 9                      2972 ± 397    3061 ± 147     10 ± 10
  SIL   964 ± 45                    1159 ± 50\*   21 ± 6                      3240 ± 281    3741 ± 278\*   16 ± 3
  TEZ   727 ± 34                    911 ± 58\*    25 ± 3                      2370 ± 156    3001 ± 232\*   26 ± 2

CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan.

\*: p \< 0.05 vs. the value obtained under baseline conditions within a group.

To illustrate the effects of the various treatments on the airway responses to MCh, the ED~50~values are compared in Figure [5](#F5){ref-type="fig"}. The BHR induced by generating a precapillary PHT by ACS was manifested in a significant decrease in ED~50~in Group CS relative to that in Group CC (p = 0.008). All of the treatments exerted a significant protective potential, leading in Groups VIP and TEZ an airway responsiveness similar to that observed in the sham operated rats (Group CC). This parameter revealed even overprotection of the airway responsiveness to MCh in Group ILO and Group SIL.

![**Equivalent dose required to cause a 50% increase in airway resistance (ED~50~) in the different groups**. CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan. \*: p \< 0.05 vs. the data obtained in the rats with precapillary pulmonary hypertension without drug treatment (Group CS).](1465-9921-12-58-5){#F5}

The relationships between the systolic Ppa and ED~50~is depicted in Figure [6](#F6){ref-type="fig"}. These parameters relating to the pulmonary haemodynamics and lung responsiveness exhibited a statistically significant correlation for the entire study population (R = -0.59, p = 0.016) and were variable for the individual study groups with closest correlation being observed in Group CS (R = -0.6) and the weakest in rats with no intervention (Group C, R = 0.1).

![**The relationships between the systolic pulmonary arterial pressure (Ppa) and the lung responsiveness expressed as the equivalent dose required to cause a 50% increase in the airway resistance (ED~50~) in the different groups**. CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan. Symbols: individual data points in each rat, thin lines: regressions for individual groups, thick line: linear regression for the pooled data.](1465-9921-12-58-6){#F6}

Discussion
==========

Various treatment strategies applied against PHT act on the imbalance between the vasoactive constrictor-proliferative and vasorelaxing-antiproliferative mediators. In the present study, we investigated whether these treatments provide protection against the enhanced airway responsiveness observed in the presence of precapillary PHT. The results obtained in this well-validated animal model of BHR originating from precapillary PHT induced by ACS preparation demonstrate that all the treatment modes studied, including the action on the VIP, PC, NO and ET-1 pathways, exhibited a beneficial profile in preventing the development of BHR. Pooling of all the data points obtained from the groups revealed that the systolic Ppa level and the magnitude of the lung responsiveness were associated.

It was earlier reported \[[@B11]\] that the creation of an ACS led to precapillary PHT, which was associated with enhanced airway responsiveness to MCh. This experimental model has been extensively validated previously both by ourselves and by other research groups, and has been proved to provide an increased pulmonary blood flow leading to PHT \[[@B11]-[@B13],[@B20]\]. Precise measurement of the pulmonary haemodynamics in rats was complicated by the small size of the animal and the lack of catheter-tip balloon, which normally helps to introduce to the pulmonary artery. Due to this technical difficulty, technically acceptable Ppa recordings were possible only in about two-third of the rats. According to literature \[[@B11],[@B13],[@B20]\], we also noted an elevated systolic Ppa in the rats in Group CS, confirming the validity of the experimental model for investigation of the pulmonary consequences of chronic precapillary PHT. It is noteworthy, however, that the model applied here mimics clinical conditions encountered in patients with left-to-right shunts and increased pulmonary blood flow, and the results may not be extrapolated to other forms of PHT. The altered mechanical interdependence between the pulmonary vasculature and the respiratory tract is responsible for the BHR in this experimental model, thus the effects of the applied treatment strategies in the present study are valid for this pulmonary haemodynamical abnormality.

In agreement with previous data \[[@B11]\], we did not observe statistically significant changes in the baseline values of the respiratory mechanical parameters following sustained precapillary PHT. However, normalization of the Raw to the lung volume revealed a statistically significant increase in this specific Raw (p \< 0.006), which is in harmony with the earlier results that ACS causes a detectable elevation only in the corrected baseline Raw. Accordingly, it can be anticipated that the experimental model applied here reflects the major features of the respiratory mechanical changes encountered under baseline conditions in patients with chronic precapillary PHT.

The three major mechanisms involved in the development of PHT are the PC, the ET and NO pathways. The pathological changes in these pathways are manifested by an imbalance of the mediators with vasodilation or vasoconstriction potential. These pathways have also been implicated in the regulation of the airway smooth muscle tone \[[@B8],[@B10],[@B21],[@B22]\]. Thus, we restored an optimum balance between the constrictor/dilator mediators through selective targeting of these mechanisms to characterize whether these treatment strategies affect lung responsiveness.

Iloprost is a PC analogue and a potent pulmonary vasodilator that exerts its effect through the activation of cyclic adenosine monophosphate (cAMP) \[[@B2]\]. Since the molecule has a short half-life (approximately 20 min), we followed the common strategy of delivering it via a continuous infusion. In agreement with previous findings, this treatment strategy effectively inhibited the PHT \[[@B23],[@B24]\]. Over and above this well-established beneficial pulmonary vascular effect, our study is the first to demonstrate that this pharmacotherapeutic management is associated with complete prevention of the development of BHR.

Another essential pathway involved in the pathogenesis of PHT is related to a dysfunction in the key pulmonary vasodilator NO \[[@B25]\]. Enhancement of the NO-mediated effects by phosphodiesterase 5 inhibitors such as sildenafil has therefore been proposed as an effective mode of treatment against PHT \[[@B9],[@B26]\]. NO is known to exert a potent bronchodilation effect \[[@B27]\], and its overexpression leads to a direct relaxing effect on the airway smooth muscle. Since excessive NO in the lungs has been shown to inhibit MCh-induced bronchoconstriction \[[@B28]\], this mechanism is probably involved in the complete prevention of BHR in Group SIL in the present study.

The rationale of testing the ability of tezosentan, a dual ET-1 receptor antagonist, to prevent BHR emerged from the crucial involvement of ET-1 in the pathogenesis of PHT \[[@B25]\]. ET-1 exerts its regulatory effect on the pulmonary vascular and bronchial tone via two receptor subtypes (ET~A~and ET~B~). The roles of these receptor subtypes on the pulmonary vascular and bronchial tone are dissociated, with ET~A~stimulation leading to vasoconstriction and bronchodilation \[[@B10],[@B29]\], while activation of ET~B~receptors results in the liberation of vasodilator mediators with a concomitant bronchodilation potential \[[@B10],[@B30]\]. The opposing effects of ET~A~and ET~B~following dual receptor blockade may therefore have resulted in the lack of significant change in the Ppa in the present study. However, the similar abilities of ET~A~and ET~B~to relax the airway smooth muscle are reflected in the potential of tezosentan to prevent BHR effectively. This raises the unsolved controversy of the use of specific ET~A~or dual blockers: clinical studies have so far failed to reveal significant differences between selective ET~A~and dual receptor blockade \[[@B31]\]. However, our data suggest that the detrimental effects of precapillary PHT can be effectively prevented by dual ET-1 receptor blockade.

VIP plays a major role in regulating the smooth muscle tone around both the pulmonary vasculature and the bronchi via the non-adrenergic non-cholinergic nervous system \[[@B32]-[@B34]\]. Since VIP exerts its relaxation potential on the smooth muscle by opening Ca^2+^-activated K^+^channels through a cAMP-dependent mechanism \[[@B35],[@B36]\] and by inducing NO release from VIP/NO-containing nerve fibers and the endothelium \[[@B32],[@B37]\], its inhalation has recently been advocated in the treatment of PHT \[[@B38],[@B39]\]. Although previous studies have suggested the efficacy of this peptide in inducing transient pulmonary vasodilation in another model of PHT \[[@B39]\], our findings indicate that the chronic continuous intraperitoneal administration of VIP did not provide a decrease in Ppa in the presence of precapillary PHT. However, BHR was eliminated by VIP treatment, which is in accord with previous results demonstrating its bronchodilation properties \[[@B10],[@B40]\].

Summary and conclusions
-----------------------

This comparison of treatment strategies aimed at reestablishment of the balance between the various smooth muscle constrictor and relaxation mediators revealed similar abilities of the agonists acting on the PC, NO, ET-1 and VIP pathways to protect the development of airway hyperreactivity subsequent to precapillary PHT. The pathophysiological mechanisms responsible for the fairly uniform bronchial effects of the various treatments may be inferred from the significant correlation between the lung responsiveness and the level of systolic PHT (Figure [6](#F6){ref-type="fig"}). This close association suggests that independently of the pharmacotherapeutical approach to influence the pulmonary vasculature, it is the level of Ppa which determines the lung responsiveness through the existence of a close mechanical interdependence between the pulmonary vasculature and the airway tree.
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